esr1 mutations
Gut Health
FDA approves Camizestrant for breast cancer with ESR1 mutations
The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment option and its clinica